Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
BHVN Price and Sentiment
BHVN Latest news
Biohaven's (BHVN) sole marketable drug, Nurtec ODT reports preliminary sales for the third quarter, which beat expectations.
Biohaven Announces Preliminary 3Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For Both Acute And Preventive Treatment2021-10-05 07:30
NEW HAVEN, Conn., Oct. 5, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
Biohaven's (BHVN) myeloperoxidase enzyme inhibitor, verdiperstat fails to statistically differentiate from placebo in improving disease progression in patients with multiple system atrophy in a late-stage study.
Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) has announced results from a focused analysis of verdiperstat trial in verdiperstat in multiple system atrophy (MSA). Verdiperstat did not differ statistically from placebo on the prespecified primary efficacy measure or the key secondary efficacy measures.
NEW HAVEN, Conn., Sept. 27, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
Biohaven Spotlights Nurtec® ODT (rimegepant), the only dual-therapy indicated for both the acute and preventive treatment of migraine, at the 2021 International Headache Society - European Headache Federation Joint Congress2021-09-09 07:30
NEW HAVEN, Conn., Sept. 9, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) reported earnings 30 days ago.
Tuesday Afternoon Analyst Upgrades and Downgrades: SmileDirectClub, Squarespace, Victoria's Secret and More2021-08-10 12:56
With the trading day more than halfway over, the broad markets were mixed yet again, but this came with a couple of record highs.
Biohaven's (BHVN) sole approved drug, Nurtec ODT for treating migraine continues to demonstrate strong demand in the United States. Higher operating expense drags down the bottom line.
Biohaven Pharmaceutical Holding Company's (BHVN) CEO Vlad Coric on Q2 2021 Results - Earnings Call Transcript2021-08-09 13:53
Biohaven Pharmaceutical Holding Company's (BHVN) CEO Vlad Coric on Q2 2021 Results - Earnings Call Transcript